Bladder Cancer: Clinical Trials

1,125 trials for Bladder Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

491 completed, 184 unknown, 181 recruiting, 108 terminated. 322 Phase 2, 263 Not applicable, 189 Phase 1, 107 Phase 3, 16 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2322Completed 153, Terminated 52, Recruiting 35, Active not recruiting 33, Unknown 30, Not yet recruiting 10, Withdrawn 9
Not applicable263Completed 122, Recruiting 53, Unknown 42, Terminated 13, Active not recruiting 12, Not yet recruiting 10, Withdrawn 8, Enrolling by invitation 3
Phase 1189Completed 86, Recruiting 28, Terminated 26, Active not recruiting 17, Unknown 13, Withdrawn 12, Not yet recruiting 7
Phase 3107Completed 45, Unknown 20, Terminated 14, Recruiting 12, Active not recruiting 8, Not yet recruiting 4, Withdrawn 4
Phase 416Completed 6, Unknown 6, Withdrawn 2, Not yet recruiting 1, Recruiting 1
Early Phase 113Completed 9, Active not recruiting 2, Not yet recruiting 1, Terminated 1

Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Naloxegol in the Prevention of POI After Cystectomy
Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications
Phase 2WithdrawnInstitut Paoli-Calmettes2032-01-012026-10-14
Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer
AI Uro-Cam - Bladder Cancer
Not applicableNot yet recruitingChinese University of Hong Kong602028-07-012026-10-28
Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
ATO-101™ - Bladder Cancer
Phase 1Not yet recruitingInstitut Cancerologie de l'Ouest242027-01-012026-06-08
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer
Phase 1Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University202027-01-012026-11-05
The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC
ERBT and Adjuvant MMC Therapy, ERBT - Bladder Cancer
Not applicableNot yet recruitingChinese University of Hong Kong4402027-01-012026-10-30
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma
Phase 1Not yet recruitingImmunityBio, Inc.182026-12-012026-09-24
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids
Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer
Phase 2Not yet recruitingHospital Centre Biel/Bienne282026-12-012026-09-18
Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer
Transurethral Resection of Bladder Tumor, Sequential Systemic Chemotherapy, radiotherapy - Bladder Cancer, TURBT
Phase 3Not yet recruitingAssiut University712026-12-012026-11-03
A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies
Metastatic Urothelial Carcinoma, Urothelial Cancer
Active not recruitingPfizer51222026-11-042026-11-18
MyPatientPal+: A Smartphone App and a Provider Dashboard to Manage Patient Care While on Treatment
MyPatientPal+ - Breast Cancer, Gastrointestinal Cancer
Not applicableNot yet recruitingBarbara Ann Karmanos Cancer Institute1002026-11-012026-11-10
A Phase II, Prospective, Single-center Study of FAPI PET Imaging and Liquid Biopsy in Bladder Cancer
FAPI PET/CT with [68Ga]Ga-BED003, ctDNA/utDNA liquid biopsy - Bladder Cancer
Phase 2Not yet recruitingChiti Arturo2622026-11-012026-11-16
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer
Phase 3RecruitingSystImmune Inc.5202026-11-012026-11-18
Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
Proton Transfer Reaction Mass Spectrometry Analysis - Pancreas Cancer, Hepatocellular Carcinoma
Not yet recruitingUniversity of Oklahoma20002026-11-012026-11-18
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer
Phase 3RecruitingMerck Sharp & Dohme LLC4002026-10-232026-11-16
Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
Conventional Transurethral Resection of Bladder Tumour, Transurethral En Bloc Resection of Bladder Tumour - Bladder Cancer
Not applicableRecruitingChinese University of Hong Kong7322026-10-192026-10-27
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
Enfortumab vedotin, Pembrolizumab, Cisplatin - Bladder Cancer, Urothelial Carcinoma
Phase 2RecruitingFox Chase Cancer Center702026-10-162026-11-02
Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients
Hyperthermic Intravesical Chemotherapy (HIVEC) - Non Muscle Invasive Bladder Cancer, Bladder Cancer
Not applicableNot yet recruitingAC.TA. S.r.l.502026-10-152026-05-06
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Acupuncture, Exercise - Metastatic Bladder Cancer, Peripheral Neuropathy
Not applicableRecruitingDana-Farber Cancer Institute202026-09-032026-10-26
Bladder Preservation or Cystectomy for MIBC
Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Early Phase 1Active not recruitingDana-Farber Cancer Institute202026-09-022026-09-15
A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure
Intravesical Instillation of Disitamab Vedotin Combined with Toripalimab - Bladder Cancer
Phase 1Not yet recruitingXiangya Hospital of Central South University202026-09-012026-08-25

Showing 20 of 1125. Sign in to see all of them.

Narrower conditions

Urinary Bladder Neoplasms (1125)  ·  Carcinoma, Transitional Cell (112)  ·  Prostatic Neoplasms (112)  ·  Ovarian Neoplasms (95)  ·  Lung Neoplasms (91)  ·  Breast Neoplasms (86)  ·  Carcinoma, Non-Small-Cell Lung (84)  ·  Colorectal Neoplasms (81)  ·  Kidney Neoplasms (80)  ·  Non-Muscle Invasive Bladder Neoplasms (80)  ·  Pancreatic Neoplasms (79)  ·  Stomach Neoplasms (76)  ·  Neoplasms (69)  ·  Head and Neck Neoplasms (65)  ·  Esophageal Neoplasms (64)

Broader conditions

Female Urogenital Diseases (1125)  ·  Female Urogenital Diseases and Pregnancy Complications (1125)  ·  Male Urogenital Diseases (1125)  ·  Urogenital Diseases (1125)  ·  Neoplasms by Site (1124)  ·  Urologic Diseases (1116)  ·  Urogenital Neoplasms (1115)  ·  Urinary Bladder Diseases (1109)  ·  Urologic Neoplasms (1107)  ·  Neoplasms (1056)  ·  Neoplasms by Histologic Type (328)  ·  Neoplasms, Glandular and Epithelial (299)  ·  Carcinoma (283)  ·  Genital Diseases (192)  ·  Digestive System Diseases (168)

Interventions

Gemcitabine (101)  ·  Cisplatin (78)  ·  pembrolizumab (44)  ·  Paclitaxel (32)  ·  Cystectomy (29)  ·  Mitomycin (28)  ·  Carboplatin (26)  ·  Docetaxel (25)  ·  Radiotherapy (25)  ·  BCG Vaccine (22)  ·  atezolizumab (22)  ·  Nivolumab (18)  ·  Doxorubicin (17)  ·  durvalumab (16)  ·  Cystoscopy (14)

Sponsors

Memorial Sloan Kettering Cancer Center (44)  ·  M.D. Anderson Cancer Center (21)  ·  Mansoura University (20)  ·  National Cancer Institute (NCI) (19)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (18)  ·  UNC Lineberger Comprehensive Cancer Center (14)  ·  University of Kansas Medical Center (14)  ·  European Organisation for Research and Treatment of Cancer - EORTC (12)  ·  SWOG Cancer Research Network (12)  ·  Assiut University (10)  ·  Chinese University of Hong Kong (9)  ·  Dana-Farber Cancer Institute (9)  ·  Merck Sharp & Dohme LLC (9)  ·  Photocure (9)  ·  The First Affiliated Hospital with Nanjing Medical University (9)

Countries

United States (528)  ·  China (121)  ·  United Kingdom (88)  ·  Canada (83)  ·  France (79)  ·  Italy (72)  ·  Spain (68)  ·  Denmark (48)  ·  Australia (44)  ·  Netherlands (42)  ·  Germany (41)  ·  South Korea (37)  ·  Belgium (36)  ·  Egypt (33)  ·  Poland (26)

Top investigators

Dean Bajorin, MD (7)  ·  Ahmed Mosbah, MD (6)  ·  Amr A Elsawy (6)  ·  Dean F. Bajorin, MD (6)  ·  Jian Huang, MD (6)  ·  Andrea B Apolo, M.D. (4)  ·  Eugene Lee, MD (4)  ·  Ali Kaan Yildiz (3)  ·  Arlene Siefker-Radtke, MD (3)  ·  Armine Smith, MD (3)

Results publications

PMID 38045238, PMID 38167321, PMID 16389183, PMID 11001674, PMID 17409436, PMID 17452976, PMID 19687335, PMID 20850152, PMID 22512481, PMID 22877502, PMID 23982601, PMID 24373477, PMID 25150172, PMID 25366678, PMID 25651787, PMID 26952546, PMID 27939400, PMID 28453896, PMID 29141603, PMID 29203268, PMID 29489427, PMID 29562804, PMID 33241650, PMID 33408185, PMID 33539743, PMID 37496366, PMID 39069239, PMID 41044356, PMID 41074972, PMID 10519404, PMID 11224527, PMID 11229684, PMID 11844814, PMID 11923603, PMID 12032861, PMID 12091876, PMID 12118019, PMID 12136861, PMID 12448661, PMID 12525530, PMID 12538684, PMID 12586807, PMID 12767086, PMID 12913696, PMID 1355007, PMID 14529770, PMID 14734003, PMID 15030777, PMID 15073851, PMID 15093567

NIH funding

U10CA032102 (10), 2017 (9), 2019 (7), 2023 (6), 2018 (5), P50CA091846 (5), 2014 (4), R01CA198887 (4), 2025 (3), 2015 (2), 2016 (2), P30CA016672 (2), P30CA138292 (2), U10CA031946 (2), 2005 (1)